David Cucchiari, Alicia Molina-Andujar, Enrique Montagud-Marrahi, Ignacio Revuelta, Jordi Rovira, Pedro Ventura-Aguiar, Gastón J Piñeiro, Erika De Sousa-Amorim, Nuria Esforzado, Frederic Cofán, Jose-Vicente Torregrosa, Jessica Ugalde-Altamirano, M José Ricart, Francisco J Centellas-Pérez, Manel Solè, Jaume Martorell, José Ríos, Josep M Campistol, Fritz Diekmann, Frederic Oppenheimer
BACKGROUND: It is commonly believed that mTOR inhibitors (mTORi) should not be used in high-immunological risk kidney transplant recipients, due to a perceived increased risk of rejection. However, almost all trials that examined the association of optimal-dose mTORi with Calcineurin Inhibitor (CNI) have excluded hypersensitized recipients from enrollment. METHODS: To shed light on this issue, we examined 71 consecutive patients with a baseline cPRA ≥ 50% that underwent kidney transplantation from June 2013 to December 2016 in our Unit...
October 21, 2019: Transplantation